Company Overview of aTyr Pharma Inc.
aTyr Pharma Inc. is a protein therapeutics company that discovers and develops biologic therapeutics based on physiocrines. It focuses on the discovery of phyisiocrines, which are a class of endogenous human proteins from amino acyl tRNA synthetases that function as extracellular signaling molecules in various physiologic settings; and the development of physiocrine-based medicines for indications in the areas of hematology, immune modulation, infection, and metabolism. The company’s lead product is Tmax, which is in preclinical development for thrombocytopenia. aTyr Pharma Inc. was incorporated in 2005 and is based in San Diego, California.
3545 John Hopkins Court
San Diego, CA 92121
Founded in 2005
Key Executives for aTyr Pharma Inc.
Executive Chairman and Chief Executive Officer
President and Chief Operating Officer
Associate Director of Discovery Research
Compensation as of Fiscal Year 2014.
aTyr Pharma Inc. Key Developments
aTyr Pharma Receives EMA Orphan Drug Designation for Resolaris™ in FSHD
Feb 18 15
aTyr Pharma Inc. announced the European Commission has granted orphan drug designation to Resolaris for the treatment of
facioscapulohumeral muscular dystrophy (FSHD). Resolaris, an investigational new drug representing Physiocrine-based product candidate in the clinic, is being developed as a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. aTyr previously announced the first patient study of Resolaris in adults with FSHD, a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients currently enrolling at multiple sites in the European Union (EU). EMA orphan designation is intended to encourage development of medicines for the diagnosis, treatment, or prevention of life-threatening or chronically debilitating conditions that affect no more than 5 in 10,000 people in the EU. Medicines that receive orphan designation are eligible for a number of incentives, including assistance with development of the medicine; reduced fees for marketing-authorization applications; and extended market exclusivity once the medicine is authorized. Orphan designation is conferred following a positive opinion by the EMA's Committee for Orphan Medicinal Products (COMP).
aTyr Pharma Inc. Announces First FSHD Patient Study of Resolaris TM
Jan 26 15
aTyr Pharma announced its first FSHD patient clinical trial of Resolaris TM, an investigational new drug representing aTyr’s first Physiocrine-based product candidate in the clinic. The study focuses on adult patients with facioscapulohumeral muscular dystrophy (FSHD), a rare and severe genetic myopathy for which there are currently no approved treatments. The Phase 1b/2 study is a double-blind, placebo-controlled, multiple ascending dose trial in up to 44 FSHD patients at multiple sites in the European Union. The exploratory trial is designed to evaluate safety, tolerability, pharmacokinetics and the biological activity of Resolaris TM in adult patients with FSHD.
aTyr Pharma Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:00 AM
Dec 3 14
aTyr Pharma Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-11-2015 08:00 AM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: John D. Mendlein, Executive Chairman and Chief Executive Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|